Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Clinical trial NCT04639843 · WITHDRAWN

Trial details

NCT number: NCT04639843
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Adult T-cell Leukemia/Lymphoma Extranodal NK-/T-cell Lymphoma, Nasal Type Enteropathy-Associated T-Cell Lymphoma Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma Hepatosplenic T-cell Lymphoma

Start date: 2022-11-03
Primary completion: 2022-11-03
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.